In correlation with the DEGs results, pathways showed that benralizumab-treated patients had upregulated genes in inflammatory pathways such as IL6 Jak Stat3 Signaling, IL2 Stat5 Signaling, Complement, Interferon Alpha Response, and Interferon Gamma Response with a normalized enrichment score (NES) greater than 1.4 when compared to remission EoE and controls (Fig. 4). This evidence concerns the gene STAT3 and eosinophilic esophagitis.